Sarepta CEO Ed Kaye to resign

Sarepta Therapeutics CEO Ed Kaye said Thursday that he plans to step down from his post at the Cambridge biotech at the end of the year.Kaye, who was named interim CEO of Sarepta (Nasdaq: SRPT) in March 2015 and took on the job permanently in September 2016, announced his plan to depart during a conference call with analysts. Kaye said he will continue to serve on Sarepta's board.Last year, Sarepta won approval for Exondys 51, the first drug to treat Duchenne muscular dystrophy. The company said